|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
BCS-TC2 cells are not tumorigenic in vivo, but are able to form tumors when coinjected with FN in nude mice.
|
12138246 |
2002 |
|
Leukemia, Myelocytic, Acute
|
0.060 |
Biomarker
|
disease |
BEFREE |
Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.
|
31698332 |
2020 |
|
Ubiquinone dehydrogenase deficiency
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
BCS1L mutations are also linked to an undefined complex III deficiency, a heterogeneous condition generally involving low birth weight, renal and hepatic pathologies, hypotonia, and developmental delays.
|
30582773 |
2019 |
|
Ubiquinone dehydrogenase deficiency
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Respiratory chain complex III deficiency due to mutated BCS1L: a novel phenotype with encephalomyopathy, partially phenocopied in a Bcs1l mutant mouse model.
|
28427446 |
2017 |
|
Ubiquinone dehydrogenase deficiency
|
0.060 |
Biomarker
|
disease |
BEFREE |
Defects in five further factors for assembly (TTC19, UQCC2, and UQCC3) or iron-sulphur cluster loading (BCS1L and LYRM7) cause complex III deficiency.
|
28804536 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
90.8% of MLL-PTD AML patients had at least one additional gene mutation.
|
26375248 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.060 |
Biomarker
|
disease |
BEFREE |
The significant correlation between the expression of MDR-1, MRP-1, and BCRP mRNA and FLT3-ITD or MLL-PTD in AML patients requires further investigation.
|
24030729 |
2014 |
|
Ubiquinone dehydrogenase deficiency
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
BCS1L gene mutation presenting with GRACILE-like syndrome and complex III deficiency.
|
22277166 |
2012 |
|
Leukemia, Myelocytic, Acute
|
0.060 |
Biomarker
|
disease |
BEFREE |
Within the majority of MLL-PTD AML is a mechanism in which DNA hypermethylation silences a TSG that, together with MLL-PTD, can contribute further to aberrant chromatin remodeling and altered gene expression.
|
18566324 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.060 |
Biomarker
|
disease |
BEFREE |
FLT3-LM and MLL-PTD were more frequent in AML relapse than in de novo AML or s-AML (p<0.0001).
|
17550846 |
2007 |
|
Ubiquinone dehydrogenase deficiency
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
BCS1L mutations cause disease phenotypes ranging from highly restricted pili torti and sensorineural hearing loss (the Björnstad syndrome) to profound multisystem organ failure (complex III deficiency and the GRACILE syndrome).
|
17314340 |
2007 |
|
Leukemia, Myelocytic, Acute
|
0.060 |
Biomarker
|
disease |
BEFREE |
This review summarises clinical studies on MLL-PTD positive AML and recent experimental findings on the putative leukaemogenic role of MLL-PTD.
|
16965385 |
2006 |
|
Ubiquinone dehydrogenase deficiency
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
No significant deficiency of complex III activity of respiratory chain has been found, although we recently showed that the underlying genetic cause is a missense mutation (S78G) in the BCS1L gene and other mutations in that gene have been associated with complex III deficiency.
|
12547234 |
2003 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Fifty-six patients with breast cancer were enrolled for BCS through local or general anesthesia.
|
31662515 |
2020 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Fifty-six patients with breast cancer were enrolled for BCS through local or general anesthesia.
|
31662515 |
2020 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer.
|
30384580 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
The present studies, successfully provide a workable nanomedicine, loaded with a BCS class-IV drug, for improved efficacy and safety in breast cancer.
|
30986424 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to compare the long-term results between RT after BCS and postmastectomy RT in stage T1-2N1M0 breast cancer.
|
31372049 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
A single institution chart review evaluated all patients undergoing BCS for treatment of breast cancer.
|
30049436 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer.
|
30384580 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The present studies, successfully provide a workable nanomedicine, loaded with a BCS class-IV drug, for improved efficacy and safety in breast cancer.
|
30986424 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In this study, we aimed to compare the long-term results between RT after BCS and postmastectomy RT in stage T1-2N1M0 breast cancer.
|
31372049 |
2019 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
A single institution chart review evaluated all patients undergoing BCS for treatment of breast cancer.
|
30049436 |
2019 |
|
Malignant neoplasm of breast
|
0.090 |
Biomarker
|
disease |
BEFREE |
Since overall prognosis and systemic therapy recommendations for MBC are similar to breast cancer in women, we describe the first case of MBC treated with BCS and IORT.
|
28597470 |
2018 |
|
Breast Carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Since overall prognosis and systemic therapy recommendations for MBC are similar to breast cancer in women, we describe the first case of MBC treated with BCS and IORT.
|
28597470 |
2018 |